The development of the so-called "targeted therapies", particularly those drugs that inhibit the activity of tyrosine kinases, has become a remarkable progress in the treatment of neoplastic diseases. The small molecule tyrosine kinase inhibitor (TKI) imatinib has revolutionized the treatment of chronic myeloid leukemia, and trastuzumab, the humanized monoclonal antibody against the ERBB2 receptor tyrosine kinase, has proved to have a high efficacy in 25% of breast cancers. On the basis of treatment success it is expected that targeted therapies will spread its use in the future.
INTRODUCTION
Protein tyrosine kinases (TKs) are enzymes that catalyze the transfer of phosphate from ATP to tyrosine residues in polypeptides. The human genome contains about 90 TK and 43 TK-like genes, which regulate cellular proliferation, survival, differentiation, function, and motility [1] . TKs are divided into two main types. Receptor TKs are transmembrane proteins with a ligand-binding extracellular domain and a catalytic intracellular kinase domain. Nonreceptor TKs are found in the cytosol, the nucleus and the inner surface of the plasma membrane. The kinase domains of all TKs have a bilobar structure, with a N-terminal lobe that binds ATP and magnesium, a C-terminal lobe containing an activation loop, and a cleft between the lobes to which polypeptide substrates bind. See Fig. (1) . The enzymatic activities of both types of TK are under tight control, so that nonproliferating cells have very low levels of tyrosyl phosphorylated proteins. In the absence of ligand, receptor TKs, as platelet-derived growth factor receptor β (PDFGR β), are unphosphorylated and the conformation of their kinase domains are inactive. After activation, autophosphorylation generates binding sites *Address correspondence to this author at the Cardiology Department, Thorax Institute, Hospital Clinic, Villarroel 170; 08036 Barcelona, Spain; Tel: +34-932279305; Fax: +34-93 2275749; E-mail: xbosch@clinic.ub.es for signaling proteins, recruiting them to the membrane and activating multiple signaling pathways. The nonreceptors TKs, typified by c-ABL, are maintained in an inactive state by cellular inhibitor proteins and lipids and through intramolecular autoinhibition. Nonreceptor TKs are activated by diverse intracellular signals through dissociation of inhibitors, by recruitment to transmembrane receptors, and through trans-phosphorylation by other kinases.
Given the multiple levels of regulation of TKs, it is not surprising that TKs are dysregulated in cancer cells in several ways. A common mechanism of TK activation in hematologic cancers is the fusion of a receptor or nonreceptor TK with a protein, usually as a consequence of a balanced chromosomal translocation.
TKs can be inhibited pharmacologically through multiple mechanisms. Anti-TK drugs or tyrosine kinase inhibitors (TKI) may directly inhibit the catalytic activity of the kinase by interfering with the binding of ATP or substrates or they can block their dimerization. Antibodies against receptor TKs or their ligands interrupt TK signaling through neutralization of ligand, blockade of ligand binding, receptor internalization and perhaps antibody-mediated cytotoxicity. These agents are divided into two general types: humanized monoclonal antibodies directed against receptor tyrosine kinases or their ligands, and small-molecule tyrosine kinase inhibitors.
Targeted cancer therapies should be less toxic than conventional chemotherapy because they are supposed to be specific for tumor cells. Consistent with this expectation, a maximum tolerated dose for imatinib, the most widely used TKI designed as a specific abl inhibitor, was never reached in the phase I trials of this agent. However, after their widespread use, several clinical and basic studies have demonstrated certain degree of cardiotoxicity related to these compounds. Nevertheless, rates of cardiotoxicity associated with TKI are not well known mainly because first clinical trials usually did not include predefined cardiac endpoints or the assessment of left ventricular (LV) function before and during treatment and later trials that included cardiac monitoring usually excluded patients with cardiovascular risk factors or cardiovascular diseases. In addition, it is especially difficult to diagnose heart failure in patients with cancer who have many reasons to develop dyspnoea. Also, the clinical magnitude of the problem is not clear and uncertainty persists about the potential reversibility of the dysfunction.
In this review, we present a thorough revision about the incidence of cardiotoxicity associated to TKIs currently in use and approved by the US Food and Drug Administration (FDA). An effort to explain the mechanisms underlying this toxicity has also been made. Index Medicus (MEDLINE), Science Citation Index and Excerpta Medica were the bibliographic sources used. Clinical trials and published series of cases from January 1980 up to January 2009 were included. The following TKIs approved by 2009 by FDA for their uses in human cancer were chosen: trastuzumab, lapatinib, imatinib, dasatinib, nilotinib, sunitinib and sorafenib. Publications reporting cardiotoxicity of any of these drugs were reviewed. Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib, gefitinib, cetuximab and panitumumab were not included in the present review because these agents have not been associated with cardiotoxicity [2] .
Being aware of the risk of using these drugs is particularly important to early detect and institute the appropriate treatment to prevent irreversible myocardial injury, especially when some neoplastic diseases, as hematological cancers or breast cancer, can affect to young people with an estimated long-term survival. Moreover, some haematological cancers as chronic myeloid leukemia (CML) require longterm treatment even for life-time. In addition, the identification of targets mediating cardiotoxicity can help to guide future drug development to avoid activation of cardiac pathways but leaving tumor-cell killing intact.
ERBB2 INHIBITORS: TRASTUZUMAB AND LAPATINIB
Trastuzumab is a humanized monoclonal antibody against the ERBB2 (or HER-2) receptor tyrosine kinase which is overexpressed in 25% of human breast cancers [3] . Trastuzumab is currently approved for the treatment of HER-2-overexpressing breast cancer both in the adjuvant and the metastatic setting. The addition of trastuzumab to chemotherapy in this context has been associated with greater clinical benefits than chemotherapy alone, including a 25% increase in median survival (25.3 vs. 20 .1 months, respectively). Lapatinib is a dual tyrosine kinase inhibitor that inhibits EGFR and HER2 proteins. It is approved in combination with capecitabine for the treatment of HER-2 overexpressing breast cancer that received prior therapy including an anthracycline, a taxane and trastuzumab. The trial that led to this therapeutical indication compared capecitabine alone or in combination with lapatinib in HER2-overexpressed breast cancer patients progressing to trastuzumab. This randomized phase III trial showed a significant improvement in the progression-free survival of the women treated with the combination [4] .
Cardiotoxicity Incidence
On the basis of preclinical data and early clinical trials, treatment with trastuzumab was not expected to be associated with cardiotoxicity. Consequently, formal cardiac monitoring was not included in the trastuzumab pivotal trial protocols. However, the pivotal phase III combination trial (H0648g), designed to assess the efficacy and safety of che-motherapy in combination with trastuzumab against chemotherapy alone as first-line therapy for HER2-positive metastatic breast cancer, reported a relatively high incidence of symptomatic heart failure when trastuzumab was associated to chemotherapy (8.8% when associated with paclitaxel and 28% when associated to anthracyclines compared to 1% for paclitaxel alone or 9.6% for anthracyclines alone) [3, 5] . These data prompted the foundation of an independent Cardiac Review Evaluation Committee to monitor cardiac events in clinical trials of trastuzumab [5] . Since then, several retrospective studies have reported incidences of symptoms of heart failure or LV dysfunction as high as 35% causing discontinuation of therapy in 20% of patients [6] .
In the pivotal phase II trial of trastuzumab as second-or third-line monotherapy in patients with HER2-postive metastatic breast cancer (H0649g), symptoms of heart failure or/and a decrease in left ventricular ejection fraction >10% presented in 4.7% of patients during chemotherapy [7] . Another trial, assessing the efficacy of trastuzumab as first-line monotherapy (H0650g) in women with HER2-positive metastatic breast cancer showed an incidence of symptomatic heart failure of 2.6% [8] . Retrospective analysis of data from patients recruited to the pivotal H0649g and H0650g trials that had not received prior anthracycline therapy indicated that the rate of trastuzumab-induced heart failure was 3.3% [9] . On multivariate analysis, including patients from pivotal trials, the independent risk factors for the development of trastuzumab-associated cardiac failure included concomitant use of anthracyclines, prior anthracycline exposure, age >50 years, and NYHA functional class >II before enrolment in the trial.
Based on the incidence of heart failure observed in the pivotal trials, the adjuvant trials included serial prospective measurements of LV ejection fraction (LVEF). The Herceptin Adjuvant (HERA) trial was an international, intergroup, phase III trial involving women with HER2-positive early-stage invasive breast cancer who completed locoregional therapy and a minimum of four courses of chemotherapy [10] . In this trial 7.1% of the patients in the trastuzumab group presented a decrease in LVEF of ≥10% from baseline value or showed a LVEF <50% at any time, in comparison of a 2.2 % in the control group (p<0.001). The article of Romond et al. reported the combined results of the National Surgical Adjuvant Breast and Bowel Project trial B-31 and the North Central Cancer Treatment Group trial N9831 [11] . In trial B-31 the cumulative incidence of New York Heart Association (NYHA) class III or IV heart failure or death from cardiac causes at 3 years was 4.1% in the experimental group (vs. 0.8% in the control group) whereas in trial N9831, the 3-year cumulative incidence of NYHA class III of IV heart failure was 2.9% in the experimental group (vs. 0% in the control group). In the Breast Cancer International Research Group 006 trial, patients were randomly assigned to a nonanthracycline trastuzumab treatment versus anthracyclines followed by docetaxel with or without trastuzumab. Symptomatic events were defined as heart failure, ischemia/infarction and arrhythmia; and asymptomatic LV dysfunction as a decrease in LVEF ≥15% or below the lower limit of normality. In this trial, the incidence of symptomatic cardiac events was 2.3% vs. 1.2% for anthracyclines followed by docetaxel with or without trastuzumab, respectively; and 1.2% in the nonanthracycline-containing trastuzumab arm. Likewise, asymptomatic LV dysfunction was 2.4% vs 0.6% for anthracyclines and docetaxel with or without trastuzumab, and 0.6% vs. 0.4% in the nonanthracycline trastuzumab arm [12] . See Table 1 .
In relation to the reversibility of trastuzumab-related cardiotoxicity, of the patients included in pivotal trials with trastuzumab as second-or third-line monotherapy or in combination therapy, 6% of patients had symptomatic cardiac dysfunction. After conventional treatment with angiotensinconverting enzyme (ACE) inhibitors, diuretics and cardiac glycosides, 78% of patients experienced a significant improvement as assessed by the investigator whereas in 12% the heart failure worsened. Furthermore, symptoms improved whether trastuzumab was continued or withdrawn. Another study, by Ewer et al., reported the evolution of 38 patients with HER-2+ breast cancer referred for suspected trastuzumab-related cardiotoxicity [13] . All patients had previously received anthracycline-based chemotherapy. Mean LVEF decreased from 61±13% to 43 ±16% after trastuzumab therapy. Endomyocardial biopsy, performed in 9 patients, did not show ultrastructural changes. After withdrawal of trastuzumab, the LVEF increased in 37 of 38 patients, to a mean value of 56±11%. Mean time to recovery of LVEF was 1.5 months and was associated to medical treatment for heart failure in 32 (84%) patients. Twenty-five of these patients were re-treated with trastuzumab; of these 3 patients had recurrent LV dysfunction, and 22 did not. In B-31 trial, of the 31 women in the trastuzumab group who had congestive heart failure, 27 were followed for at least 6 months after the onset of heart failure, and only 1 patient reported persistent symptoms of heart failure.
Overall, the data from these studies suggested that trastuzumab-associated cardiotoxicity was mainly, but not solely, associated with concomitant or previous use of anthracyclines and, interestingly, the majority of cases was manageable and reversible and did not always preclude continued trastuzumab therapy.
Cardiotoxicity of lapatinib seems to be of less magnitude with the data published so far. In the trial by Geyer et al. comparing capecitabine with of without lapatinib [4] there were no symptomatic cardiac events and lapatinib was not discontinued because of a decrease in the LVEF in any case. There were also no differences in the mean LVEF values between the two groups of treatment.
Mechanisms
The mechanism of trastuzumab-induced cardiac dysfunction is not fully understood, but it is distinct from that of anthracyclines, for which the cardiotoxicity correlates with total cumulative drug dose, is irreversible and is associated with changes in myocardial ultrastructure, including vacuolization and cardiomyocyte loss [14] . By contrast, trastuzumab-associated cardiotoxicity is at least partially reversible and is not associated with ultrastructural changes.
The cardiac effects of trastuzumab could occur through several mechanisms, including drug interactions with cytotoxic chemotherapic agents, antibody-dependent cell-mediated cytotoxicity (ADCC), ERBB2 receptor down regulation and inhibition of ERBB2 signaling in cardiomyocytes. See Fig (2) .
There is significant evidence that ERBB2 has an important role in cardiomyocyte development and function. HER2 can heterodimerize with ERBB3 and ERBB4 and form a receptor for neuregulins. Neuregulins have distinct effects such as growth, differentiation and activation of survival pathways in epithelial cells, neurons and muscle cells [15] . Neuregulin signaling is essential in the developing heart. Mice that are deficient in neuregulin, ERBB2 receptors or ERBB4 receptors die in mid-gestation as a result of impaired ventricular trabeculation [16, 17] . Mice with cardiac-specific deletion of ERBB2 develop dilated cardiomyopathy and have decreased survival after pressure overload stress, which mimics severe hypertension [18] . Cardiomyocytes from these mice have increased numbers of mitochondria and vacuoles, and increased sensitivity to anthracycline. This suggests that inhibition of cardiomyocyte ERBB2 signaling by trastuzumab might be a central mechanism of the cardiotoxicity induced by this agent. However, other molecules inhibiting the same target as Lapatinib, have minimal cardiotoxicity, as early clinical results suggest [4] . In addition, ADCC might contribute to trastuzumab cardiotoxicity. Trastuzumab is an immunoglobulin G1 monoclonal antibody highly effective for mediating complement-dependent cell lyses and antibody-dependent cell-mediated cytotoxicity against ERBB2+ tumor cells in vitro. However, pertuzumab, another Ig G1 monoclonal antibody that blocks ERBB2 dimerization has been associated with a low frequency of car- diac dysfunction in early clinical trials [19] . Finally, another alternative explanation of trastuzumab cardiotoxicity is that trastuzumab in cardiomyocytes not only reduces ERBB2, but could also trigger downregulation of BCL-X L and increase expression of BCL-X S , leading to loss of mitochondrial membrane potential, a reduction in ATP levels, cytochromec release and caspase activation [20] . These changes can lead to contractile dysfunction without profound changes in cardiomyocyte ultrastructure.
ABL INHIBITORS: IMATINIB, DASATINIB AND NILOTINIB
Imatinib, dasatinib and nilotinib are ATP-competitive small-molecule inhibitors of the ABL kinase that were developed principally for the treatment of CML, in which the leukemic cells express the BCR-ABL fusion protein encoded by the Philadelphia chromosome (Ph+). Imatinib and nilotinib bind to the inactive (unphosphorylated) conformation of the ABL kinase domain, but the potency of nilotinib for BCR-ABL inhibition is about 20-fold greater than that of imatinib. In addition to ABL, both drugs also inhibit ARG (ABL-related gene or ABL2), platelet-derived growth factor receptor-α and ß (PDGFR α/ß) and KIT.
Imatinib is approved for the treatment of CML, Ph+ acute lymphoblastic leukemia (ALL), chronic myelomonocytic leukemia with PDGFR ß fusion proteins, chronic eosinophilic leukemia with PDGFR α fusion proteins, and GIST with mutations in KIT or PDGFR α. Nilotinib is currently approved for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant to prior therapy that included imatinib. The effectiveness of nilotinib is based on hematologic and cytogenetic response rates [21] . Dasatinib is at least 100-fold more active against BCR-ABL in cell-based assays, because it inhibits ABL in both the inactive and active (phosphorylated) states. Both dasatinib and nilotinib are active against some imatinib-resistant BCR-ABL mutants, and dasatinib was recently approved by the FDA for treatment of imatinib-refractory CML and Ph+ ALL.
Cardiotoxicity Incidence
In the IRIS (International Randomized Study of Interferon versus STI571) trial [22] , a randomized phase III comparison of imatinib with interferon-α and low-dose cytarabine in newly diagnosed patients with chronic phase CML, the overall incidence of heart failure was about 1%, and there was no difference between the imatinib and interferon arms. However, the lack of prospective cardiac monitoring and the fact that an important number of patients randomized to interferon 'crossed over' to imatinib, could have made imatinib-associated cardiotoxicity more difficult to be detected. The pivotal trials providing the indication of imatinib in GIST treatment [23, 24] did not monitorize cardiac function. In last years, several case-reports have been published reporting the development of heart failure symptoms and LV dysfunction while taking imatinib. After the arising of concern about cardiotoxicity of this agent, a retrospective analysis of EORTC-ISG-AGITG 62005 Trial identified a 1% heart failure incidence in 946 treated patients. Of note, cardiac assessment was based solely on patient history and physical examination [25] . Kerkela et al. [26] described a series of 10 patients developing significant LV dysfunction during therapy with imatinib mesylate. All ten individuals had normal LVEF before imatinib therapy was instituted (56±7%). After a mean of 7.2±5.4 months of therapy, patients presented with heart failure symptoms (NYHA functional class III-IV) and LVEF decline to 25±8%. Myocardial biopsies, performed on 2 of these individuals showed mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the sarco-plasmic reticulum, findings suggestive of a toxic myopathy. Previously, Park YH et al. [27] had reported the development of heart failure Fig. (2) . Possible Trastuzumab-related toxicity mechanisms in cardiomyocytes. HER2 can heterodimerize with ERBB4 and form a receptor for neuregulins (NRG1), which have several effects in growth and survival in cardiomyocytes (A). Trastuzumab might also mediate antitumor effects through T lymphocytes and produce antibody-dependent cell-mediated cytotoxicity (ADCC) (B). An increase in the ratio of BCL-Xs to BCL-X L induced by Trastuzumab might also produce mitochondrial membrane depolarization, ATP depletion, cytochrome c (Cyt c) release, and contractile dysfunction (C). in 2 patients on imatinib therapy and suggested the utility of brain natriuretic peptide for early diagnosing heart failure in this context. In these 2 cases, cardiac symptoms resolved with supportive care and withdrawal of imatinib, and in one case, the drug could be re-started without reappearance of heart failure. However, after Kerkela study was published, several reply letters emphasize the low incidence of cardiotoxicity using imatinib (0.04-1.8 per year) and especially affecting elderly patients with pre-existing cardiac conditions. Atallah E. et al. [28] published data from a retrospective analysis of 1276 patients with hematologic malignancies who had received imatinib on clinical trials at the M. D. Anderson Cancer Center from 1998 to 2006. Twenty-two patients (1.7%) were identified as having symptoms that could be attributed to cardiac failure. Of them, 15 patients had echocardiography or gated scan and 9 of the 15 patients had documented LVEF <50%. According to the authors, 18 (82%) of the 22 patients had previous cardiac conditions or cardiovascular risk factors and 13 (59%) patients had previously received known cardiotoxic drugs. It is of note that the retrospective analysis could have underestimated the incidence of cardiotoxicity and also, it is possible that subclinical cardiotoxicity might have been overlooked. However, although probably uncommon, our group described a case of a patient without any underlying cardiovascular risk factor that developed severe LV dysfunction during imatinib therapy for the treatment of a hypereosinophilic syndrome [29] . However, it can be speculated that imatinib cardiotoxicity could have been developed on a heart which was already damaged by eosinophilic infiltration. In this case, LV dysfunction was reversible after heart failure medical treatment institution and withdrawal of imatinib, Fig (3) .
There is scarce information about cardiotoxicity of dasatinib. As reported by its manufacturer (Bristol-Myers Squibb), 4% of patients taking dasatinib for a median duration of 6 months were reported to have developed heart failure or LV dysfunction. Nilotinib is believed to produce little cardiac damage. The clinical trial that stated nilotinib as a therapy for imatinib-resistant CML and Ph+ ALL reports only one patient suffering cardiac toxicity in the form of pericardial effusion and atrial fibrillation. This trial also reports an increase in the corrected QT interval by 5 to 15 msec in the study group [30] .
Mechanisms
Kerkela et al. [31] suggested in their work that imatinib's target, ABL tyrosine kinase activity, seems to have a survival function in cardiomyocytes, and its inhibition may induce apoptosis. In cardiomyocytes ABL seems to maintain endoplasmic reticulum homeostasis by mechanisms that are not clear. In cultured cardiomyocytes the authors showed that imatinib induced endoplasmic reticulum stress, leading to activation of the PKR-like ER kinase (PERK) and IRE1 pathways producing significant mitochondrial dysfunction with loss of membrane potential, release of cytochrome-c and markedly impaired energy generation with significant declines in ATP concentration; Fig (4) . Mitochondria isolated from hearts of mice treated with imatinib were also abnormal and showed increased calcium-induced opening of the mitochondrial permeability transition pore. The decline in ATP concentration observed in this study might have significant deleterious consequences on cardiomyocytes that require high energy for contraction. The identification of ABL as the relevant target suggests that newer ABL inhibitors, such as dasatinib and nilotinib may share the same mechanisms for cardiotoxicity. Nevertheless, later studies [32] have cast doubt on mitochondrial toxicity as the main event of cardiotoxicity as it had been speculated for imatinib or dasatinib, so further studies will be necessary to clarify the underlying mechanisms.
MULTI-KINASE INHIBITORS: SUNITINIB
Sunitinib and sorafenib were designed to inhibit not only tyrosine kinases involved in tumor proliferation but also tyrosine kinases involved in tumor angiogenesis such as vascular endothelial growth factor receptor (VEGFR) and PDGFR.
Sunitinib is an orally active TKI that inhibits VEGFR1-3, PDGFRα/β, KIT, FMS-related tyrosine kinase 3 and colonystimulating factor 1 receptor, being an example of a drug that target multiple receptor kinases [33] . Sunitinib is approved for the treatment of gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib and for the treatment of advanced renal cell carcinoma [34] .
Cardiotoxicity Incidence
The prescribing information for sunitinib describes that 11% of patients had declines in LVEF to below the lower limit of normal (50%). Two trials containing LV function data were published. The first trial, including patients with advanced GIST, reported no change in mean LVEF after a median treatment duration of 8 weeks [35] . The other trial, performed in patients with metastatic renal cell carcinoma, reported that 10% of patients had asymptomatic LV dysfunction after a median treatment duration of 6 months [36] . More recently, a retrospective analysis of all cardiovascular events in 75 patients with imatinib-resistant GIST who had been enrolled in a phase 1-2 trial of sunitinib, evidenced that 11% of patients that were given repeating cycles of sunitinib had a cardiovascular event, with congestive heart failure recorded in 8% of patients. Twenty-eight percent of patients treated at the approved sunitinib dose had absolute LVEF reductions of at least 10% points. Congestive heart failure and LV dysfunction generally responded to sunitinib being withheld and institution of medical management [37] . A single-institution retrospective analysis of 48 patients treated with sunitinib reported that 15% of them had symptomatic heart failure and 6.3% of the patients had persistent cardiac dysfunction after discontinuation of the drug and initiation of heart failure therapy [38] . Schmidinger M et al. reported a 33.8% incidence of any cardiac event (defined as an increase of cardiac enzymes, symptomatic arrhythmia, LV dysfunction or acute coronary syndrome) in 74 patients treated with either sunitinib (n=11) or sorafenib (n=14). Of these, 18% were symptomatic and 9.4% were seriously compromised requiring intermediate or intensive care admission. Echocardiograms were obtained in 22 patients, showing LV dysfunction in 9 patients and regional contractile abnormalities in 7 patients [39] .
Mechanisms
Although unclear, it seems that cardiotoxicity caused by sunitinib is due to an off-target effect. One possibility, suggested by Force and others [2] , could be the inhibition of both ribosomal S6 kinase and AMP-activated protein kinase (AMPK). The inhibition of S6 kinase would release the proapoptotic factor BCL2-antagonist of cell death (BAD) from RSK-mediated inactivation leading to ATP depletion and consequently to LV dysfunction. In the setting of energy compromise, normally AMPK would inhibit the energy consuming processes for protein translation and lipid biosynthe- Fig. (4) . Possible Imatinib-related toxicity mechanisms in cardiomyocytes. In cardiomyocites ABL seems to maintain endoplasmic reticulum (ER) homeostasis. The ABL inhibitor, imatinib, induces ER stress, leading to activation of the PKR-like ER kinase (PERK) and IRE1 pathways, leading to mitochondrial depolarization, ATP depletion, cytochrome c (Cyt c) release and cell death.
sis. On the other hand, sunitinib-mediated inactivation of AMPK could exacerbate any ATP depletion Fig (5) . However, more recently Hasinoff et al. [40] also investigated potential sunitinib-associated cardiotoxicity mechanisms using a neonatal rat myocyte model. They demonstrated that Sunitinib caused dose-dependent damage on myocytes at therapeutic levels and caused a dose-dependent reduction in AMPK isoforms. However, sunitinib did not affected cellular ATP levels and the toxic effect was not protected by AMPKactivating antidiabetic drug metformin. The authors concluded that the inhibition of other kinases different from AMPK is probably responsible in a higher grade for cardiotoxic effects of sunitinib.
MULTI-KINASE INHIBITORS: SORAFENIB
Sorafenib is another multi-kinase inhibitor agent that inhibits tumor growth and angiogenesis by targeting intracellular Raf kinases (CRAF, BRAF, and mutant BRAF), and cell surface kinase receptors (VEGFR-2, VEGFR-3, PDGFR-β, cKIT and FLT-3). Sorafenib is approved for the treatment of patients with unresectable hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma.
Cardiotoxicity Incidence
The prescribing information for sunitinib (Bayer Pharmaceuticals) describes that the drug can induce acute coronary syndromes, including myocardial infarction, in 2.9% of treated patients. The SHARP clinical trial assessed the efficacy of Sorafenib in patients with advanced hepatocellular carcinoma [41] . The experimental group was treated with Sorafenib 400 mg twice daily and the control group was given placebo. In the experimental group there was a 3% incidence of cardiac ischemia or infarction, similar to the 1% present in the control group. Escudier et al. [42] studied the efficacy of Sorafenib in advanced clear-cell renal-cell carcinoma. Nine hundred and three patients were assigned to receive either Sorafenib at a dose of 400 mg daily or placebo. Cardiotoxicity was present in the form of cardiac ischemia or infarction, occurring in 12 patients (3%) in the Sorafenib group and in 2 patients (<1%) in the placebo group (p=0.01).
Mechanisms
In addition to inhibiting several growth factor receptors (VEGFR2, VEGFR3, FLT3, KIT and PDGFRs), sorafenib inhibits RAF1 and BRAF. Raf family kinases are MAPK kinases functioning in the pro-survival ERK cascade, but also have ERK-independent pro-survival effects. Sorafenibmediated inhibition of RAF1 and BRAF kinase activity will disrupt signaling through the extracellular signal-regulated kinase (ERK) kinase cascade, which is believed to have a role in cell survival in the heart, especially under conditions of stress [43] . The importance of RAF1 has been demonstrated in mouse models through conditional cardiac-specific deletion of Raf1, or through cardiac-specific expression of a kinase-inactive mutant of RAF1. Deletion of Raf1 in the heart led to a dilated, hypocontractile heart with enhanced cardiomyocyte apoptosis and fibrosis [44] . It is not clear whether sorafenib simultaneously inhibits the RAF1-ASK1 interaction. If so, this would trigger activation of JNK which would lead to cytochrome c release from mitochondria and cell death. See Fig (6) . A model designed to test the contribution of direct mitochondrial functional impairment to cytotoxicity proved that sorafenib affected mitochondrial function at clinically relevant concentrations potentially contributing to its cytotoxic effect [32] There are additional concerns related specifically to inhibition of VEGF-VEGFR signaling in the heart that may be particularly relevant to patients with poorly controlled hypertension receiving sorafenib or sunitinib. Two studies using adenoviral delivery of a decoy VEGF receptor demonstrated the negative impact of interruption of VEGF-VEGFR signaling under pressure overload on the heart, resulting in marked contractile dysfunction, fibrosis and heart failure [45, 46] . Inhibition of the normal angiogenic response to pressure overload has been recently shown to be mediated by the upregulation of p53 [47] , suggesting that strategies that increase the activity of Fig. (5) . Possible Sunitinib-mediated toxicity mechanisms in cardiomyocytes. Sunitinib may inhibit the ribosomal S6 kinase (RSK) and lead to the release of the pro-apoptotic factor BCL2-antagonist of cell death (BAD) from RSK-mediated inactivation. This could lead to cytochrome c (Cyt c) release, caspase activation and ATP depletion. ATP depletion would produce left ventricular dysfunction. Normally, in a setting of energy reduction, AMP-activated protein kinase (AMPK) would inhibit the intracellular energy consuming processes. However, sunitinib-mediated inactivation of AMPK could exacerbate ATP depletion. p53 in the heart might be useful, particularly in hypertensive patients.
General Recommendations for the Use of Tyrosine Kinase Inhibitors
The cardiotoxicity of TKIs is increased in patients with coronary risk factors, prior LV disfunction and prior or concomitant treatment with anthracyclines. Accordingly, patients should be evaluated for risk factors of cardiac disease prior to begin therapy with TKI. This evaluation must include a careful history, physical evaluation and LVEF analysis by nuclear imaging or echocardiography. In patients at higher risk for cardiotoxicity, the risk/benefit ratio of treatment with TKI should be carefully evaluated. During treatment, every patient should be screened on every visit for symptoms and signs of heart failure. Regular non-invasive monitoring of LVEF may be advisable to early detect asymptomatic cardiac dysfunction. Patients who develop cardiac symptoms or LV dysfunction should be referred to a cardiologist. Pharmacological treatment in these patients is similar to that in patients with systolic LV dysfunction of any aetiology (ACE inhibitors or angiotensin receptor blockers and betablockers). Risk/benefit ratio evaluation for continuing TKI in those patients with cardiac dysfunction should consider the prognosis of each patient on an individual basis. Importantly, those who continue the therapy must be closely monitored for any evidence of cardiac deterioration.
CONCLUSION
Tyrosine kinases are dysregulated in several cancer cells and their inhibition by TKIs has improved the prognosis of some malignancies. However, some TKs have a survival function in cardiomyocytes, and their inhibition may induce cell death. Cardiomyocytes are contractile and have an extremely high demand for ATP. As a consequence, they are particularly susceptible to agents that perturb mitochondrial function. There are few clinical trials that prospectively examined TKI-mediated cardiotoxicity but data from retrospective studies and series of cases reveal that toxic effects in the heart can appear early and may be reversible after institution of medical treatment for heart failure together with withdrawal of the drug in some cases. Long-term studies are needed to support that this early reversibility of the induced LV dysfunction is maintained during longer follow-up. Being aware of the risk of using these drugs and a close relationship between haematologists/oncologists and cardiologists is particularly important to early detect and institute the appropriate treatment to prevent irreversible myocardial injury. 
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